Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

Zydus Lifesciences Limited's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 1.938000
forwardPE 22.764942
debtToEquity 34.305000
earningsGrowth 0.381000
revenueGrowth 0.169000
grossMargins 0.715810
operatingMargins 0.212270
trailingEps 48.930000
forwardEps 0.000000

ZYDUSLIFE's current ratio of 1.938 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. ZYDUSLIFE's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
ZYDUSLIFE's Forward PE is in a favorable range, suggesting the stock is reasonably priced relative to its earnings. This indicates the stock is not overpriced, providing room for potential growth and making it an attractive option for investors looking for solid value and future upside.
ZYDUSLIFE's positive earnings and revenue growth signal that the company is expected to expand its business. The company's increasing profits and sales reflect strong financial health, suggesting continued growth and success in the coming periods.
ZYDUSLIFE's positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

Over time, Zydus Lifesciences Limited's price projections have consistently been revised lower. This downward shift suggests analysts are becoming more cautious about the company's future, possibly due to emerging risks or challenges.

Insider Transactions:

Insider Transactions for ZYDUSLIFE
Insider Transactions for ZYDUSLIFE


There were 1 transactions to buy ZYDUSLIFE stock, with market price of 951.4000244140625.The period under consideration saw no buy transactions.ZYDUSLIFE's current price levels have seen more sells, possibly signaling bearish sentiment. If this trend remains unchanged, the stock could experience further declines as more investors opt to sell rather than hold their positions.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


Analysts' recent buy bias toward Zydus Lifesciences Limited suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see Zydus Lifesciences Limited as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.